Irish drugmaker Mallinckrodt and a U.S. subsidiary will pay $100 million and agree to other conditions to settle government antitrust allegations they unlawfully prevented competition for Acthar, a drug that has seen enormous price spikes in recent years.
from WSJ.com: US Business http://ift.tt/2iKytQo
via IFTTT
No comments:
Post a Comment